Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | CASP7 | P55210 | 2/20 | 0.35 |
| ▸ | CASP6 | P55212 | 2/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CDC25B | P30305 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 5/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | FER | P16591 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419975 | 0.78 | GSK3B (0.46) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL28660 | 0.77 | GSK3B (0.44) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL3104508 | 0.67 | — | — | |
| SCHEMBL10974212 | 0.65 | GSK3B (0.37) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL1450780 | 0.64 | CA12 (0.45) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL1438260 | 0.64 | CA12 (0.36) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL29651311 | 0.63 | GSK3B (0.94) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL8123268 | 0.63 | LRRK2 (0.55) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL12319785 | 0.63 | LRRK2 (0.55) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL27902018 | 0.61 | GSK3B (0.88) | GSK3BCASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828192-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | claimed |
| WO-2006068978-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTIAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | WO | claimed |
| EP-0677519-A1 | CHROMAN DERIVATIVE AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 1995-10-18 | — | — | EP | claimed |
| EP-2313422-B1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-8404838-B2 | Inhibitors of tyrosine kinase receptor dimerization | WASHINGTON UNIVERSITY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110312919-A1 | INHIBITORS OF TYROSINE KINASE RECEPTOR DIMERIZATION | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2313422-A2 | NUCLEOSIDE CYCLICPHOSPHATES | Pharmasset, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2003086395-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003035615-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035619-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-5719155-A | CARDIOVASCULAR DISORDERS | JAPAN TOBACCO INC. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0712398-A1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER LTD (GB) | 1996-05-22 | — | — | EP | disclosed |
| EP-0677519-A1 | CHROMAN DERIVATIVE AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995004730-A1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER LIMITED (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | GSK3B 1097/4885CASP3 1239/4885CASP7 1538/4885 |
| US-20110312919-A1 | INHIBITORS OF TYROSINE KINASE RECEPTOR DIMERIZATION | ERBB2, EGFR, ERBB4 | GSK3B 940/4885CASP3 3974/4885CASP7 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.